Normosang (Human Hemin)

Human Hemin provides external heme that replenishes intracellular heme stores. The increased heme level feeds back to inhibit aminolevulinic acid synthase (ALAS1), the first enzyme in the heme biosynthetic pathway, thereby reducing the synthesis of aminolevulinic acid and porphobilinogen, the toxic intermediates that trigger porphyria crises.

The dose of Normosang is individualized and set by the treating physician based on the severity of the porphyria attack, the patient’s weight, renal function, and response to therapy. No fixed dosing regimen is provided here; clinicians calculate the appropriate amount for each case.

Safety data for Human Hemin during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional after careful assessment.

To request Normosang, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.

The primary alternative to Normosang is other hemin preparations such as Panhematin. Both deliver exogenous heme and act via the same feedback inhibition of ALAS1. Differences may lie in formulation, packaging, and regulatory approvals, but clinical efficacy and safety profiles are generally comparable when used according to prescribing information.

Normosang should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The lyophilized powder should be reconstituted with the appropriate diluent immediately before intravenous administration and used within the time frame specified in the product label.

Normosang is supplied as a lyophilized powder for solution for injection. After reconstitution, it is administered intravenously, typically as a slow infusion under medical supervision. Administration settings include hospitals or specialized infusion centers where vital signs and infusion reactions can be monitored.

The most serious adverse events include acute hemolytic anemia, especially in patients with glucose‑6‑phosphate dehydrogenase deficiency, severe allergic or anaphylactic reactions, and thrombophlebitis or venous thrombosis at the infusion site. Prompt recognition and management of these events are essential.

Normosang is contraindicated in patients with known hypersensitivity to human hemin or any of its excipients, and it should be avoided in individuals with confirmed G6PD deficiency due to the risk of hemolysis. Use in patients with uncontrolled renal impairment should be carefully evaluated by a physician.